HOUSTON, April 15, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the
"Company"), a biotechnology company specializing in the
development of novel treatments for brain tumors, today announced
that CEO, John M. Climaco, will be
issuing a shareholder webinar on April
22nd, 2020 at 4:30pm
ET to discuss the Company's novel DNA-binding agent, WP1244,
and to provide an update on both the development of WP1122 through
its strong relationship with WPD Pharmaceuticals in Poland, and a glioblastoma survivor treated
with Berubicin.
Details of the webinar are below:
Date:
|
April
22nd, 2020
|
Time:
|
4:30-5:00pm
ET
|
Link:
|
https://cnspharma.com/webinar-april-2020/
|
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is
a biotechnology company specializing in the development of novel
treatments for primary and metastatic brain and central nervous
system tumors. Its lead candidate Berubicin is proposed for
the treatment of glioblastoma, a type of brain cancer currently
considered incurable, as well as for pancreatic and ovarian
cancers, and lymphomas. The Company entered into an
intellectual property (IP) agreement with Houston Pharmaceuticals,
Inc. and a Purchase Agreement with Reata. For more
information, visit www.cnspharma.com.
Forward-Looking Statements
Some of the statements in
this release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements relate to future events, future
expectations, plans and prospects. Although CNS believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. CNS has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under Item 1A. "Risk Factors" in our most recently filed
Form 10-K filed with the Securities and Exchange Commission ("SEC")
and updated from time to time in our Form 10-Q filings and in our
other public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. CNS undertakes
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-shareholder-webinar-to-discuss-collaboration-with-wpd-pharmaceuticals-for-developing-coronavirus-drug-candidates-the-significance-of-wp1244-and-an-update-on-the-cancer-free-survivor-treated-with-ber-301040816.html
SOURCE CNS Pharmaceuticals, Inc.